Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 31 -40 of 155 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/11/2008 First Published: 1/24/2005


31.		Phase II Study of Cetuximab in Patients With Recurrent or Stage IIIB or IV Bronchoalveolar Carcinoma (BAC) or Adenocarcinoma of the Lung With BAC Features

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				ECOG-E1504 E1504, NCT00103207


32.		Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				NEAR L-284/2004 NCT00115518

Last Modified: 10/11/2007 First Published: 5/5/2006


33.		Phase II Study of Cisplatin, Fluorouracil, Cetuximab, and Radiotherapy in Patients With HIV-Associated Stage I-IIIB Anal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				AMC-045 AMC-045, AMC-026, NCT00324415


34.		Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				05-113 NCT00130689


35.		Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				CELIM NCT00153998


36.		Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 75				Other				GORTEC-TREMPLIN NCT00169247


37.		Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				2005-001098-82 NCT00240682

Last Modified: 6/22/2007 First Published: 1/6/2006


38.		Phase II Study of an Individualized Drug Treatment Selection Process Based on a Tumor Xenograft Model for Patients With Resectable Pancreatic Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				JHOC-J0507 JHOC-05041402, NCT00276744


39.		Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 80				Other				62202-655 NCT00251381

Last Modified: 5/13/2008 First Published: 3/17/2006


40.		Phase II Study of Sargramostim Plasmid DNA Pancreatic Tumor Cell Vaccine, Cyclophosphamide, and Cetuximab in Patients With Metastatic or Locally Advanced Adenocarcinoma of the Pancreas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				JHOC-J0501 JHOC-05021103, JHOC-05042610, BMS-CA225247, NCT00305760

Select All on One Page


					< Previous 1 2 3 4 5 6 7 Next >

| | | | | | | |

A Service of the National Cancer Institute